Zevra Therapeutics
Yahoo Finance • 8 days ago
As U.S. profit margins near record highs, these small-cap stocks lead on profitability
[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data fr... Full story
Yahoo Finance • 28 days ago
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced th... Full story
Yahoo Finance • last month
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Ze... Full story
Yahoo Finance • 3 months ago
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement und... Full story
Yahoo Finance • 4 months ago
Zevra Turns Profitable In 2025 On Strong Uptake Of MIPLYFFA For Niemann-Pick Disease Type C
(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) has reported its fourth quarter and full-year 2025 financial results, marking a sharp turnaround from losses in 2024 as sales of its rare disease therapy MIPLYFFA accelerated. MIPLYFFA (Arimoclo... Full story
Yahoo Finance • 5 months ago
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the pr... Full story
Yahoo Finance • 5 months ago
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that i... Full story
Yahoo Finance • 7 months ago
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the ap... Full story
Yahoo Finance • 7 months ago
Zevra Therapeutics, Inc. Announces CFO Transition
CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that it... Full story
Yahoo Finance • 8 months ago
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
2025 EPS of $(0.01) Q32025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEW... Full story
Yahoo Finance • 8 months ago
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that m... Full story
Yahoo Finance • 8 months ago
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it wil... Full story
Yahoo Finance • 9 months ago
Zevra Therapeutics rises amid takeover speculation
[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images Z... Full story
- COLL
Mentioned:
Yahoo Finance • 9 months ago
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA off... Full story
Yahoo Finance • 10 months ago
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLY... Full story
Yahoo Finance • 10 months ago
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four p... Full story
Yahoo Finance • 10 months ago
Zevra Therapeutics to Participate at Upcoming Investor Conferences in September
CELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that m... Full story
Yahoo Finance • 10 months ago
Zevra Therapeutics gains amid takeover speculation
[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images Z... Full story
Yahoo Finance • 10 months ago
Zevra Therapeutics stock price target lowered to $18 at Citizens JMP
Investing.com - Citizens JMP lowered its price target on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) to $18.00 from $19.00 on Wednesday while maintaining a Market Outperform rating. According to InvestingPro data, the stock has delivered an imp... Full story
Yahoo Finance • 10 months ago
Zevra Revenue Jumps 486 Percent in Q2
Key Points GAAP revenue rose to $25.9 million in Q2 2025, exceeding estimates by 14.8%, on strong MIPLYFFA sales and French EAP expansion. GAAP net income reached $74.7 million in Q2 2025, reversing a loss from the prior year, but was fue... Full story